[go: up one dir, main page]

PT3093663T - Previsão do risco de eventos cardíacos adversos maiores - Google Patents

Previsão do risco de eventos cardíacos adversos maiores

Info

Publication number
PT3093663T
PT3093663T PT16166093T PT16166093T PT3093663T PT 3093663 T PT3093663 T PT 3093663T PT 16166093 T PT16166093 T PT 16166093T PT 16166093 T PT16166093 T PT 16166093T PT 3093663 T PT3093663 T PT 3093663T
Authority
PT
Portugal
Prior art keywords
cardiac events
major adverse
adverse cardiac
predicting risk
predicting
Prior art date
Application number
PT16166093T
Other languages
English (en)
Inventor
R Heyman Eugene
V Snider James
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of PT3093663T publication Critical patent/PT3093663T/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
PT16166093T 2008-04-18 2009-04-17 Previsão do risco de eventos cardíacos adversos maiores PT3093663T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4615808P 2008-04-18 2008-04-18

Publications (1)

Publication Number Publication Date
PT3093663T true PT3093663T (pt) 2018-10-19

Family

ID=41199760

Family Applications (4)

Application Number Title Priority Date Filing Date
PT97318422T PT2269063E (pt) 2008-04-18 2009-04-17 Predição do risco de eventos cardíacos adversos maiores
PT16166093T PT3093663T (pt) 2008-04-18 2009-04-17 Previsão do risco de eventos cardíacos adversos maiores
PT131790552T PT2660599E (pt) 2008-04-18 2009-04-17 Predição do risco de eventos cardíacos adversos maiores
PT141778464T PT2827152T (pt) 2008-04-18 2009-04-17 Previsão do risco de eventos cardíacos adversos maiores

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT97318422T PT2269063E (pt) 2008-04-18 2009-04-17 Predição do risco de eventos cardíacos adversos maiores

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT131790552T PT2660599E (pt) 2008-04-18 2009-04-17 Predição do risco de eventos cardíacos adversos maiores
PT141778464T PT2827152T (pt) 2008-04-18 2009-04-17 Previsão do risco de eventos cardíacos adversos maiores

Country Status (13)

Country Link
US (5) US8090562B2 (pt)
EP (5) EP3093663B1 (pt)
JP (6) JP5526122B2 (pt)
AU (3) AU2009236109B2 (pt)
CA (1) CA2720674A1 (pt)
DK (4) DK2827152T3 (pt)
ES (4) ES2590213T3 (pt)
HR (2) HRP20131100T1 (pt)
HU (2) HUE039963T2 (pt)
PL (4) PL2827152T3 (pt)
PT (4) PT2269063E (pt)
SI (4) SI3093663T1 (pt)
WO (1) WO2009129454A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
SI2336359T1 (sl) 2002-05-09 2016-08-31 The Brigham And Women's Hospital, Inc. 1L1RL-1 kot marker kardiovaskularne bolezni
ES2646142T3 (es) 2006-04-24 2017-12-12 Critical Care Diagnostics, Inc. Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2
US20090305265A1 (en) * 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PL2482078T3 (pl) 2006-05-01 2016-08-31 Critical Care Diagnostics Inc Diagnozowanie choroby sercowo-naczyniowej
PL2019965T3 (pl) * 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
US9968266B2 (en) 2006-12-27 2018-05-15 Cardiac Pacemakers, Inc. Risk stratification based heart failure detection algorithm
HUE039963T2 (hu) 2008-04-18 2019-02-28 Critical Care Diagnostics Inc Súlyos káros szívesemények rizikójának elõrejelzése
ES2795003T3 (es) * 2008-10-07 2020-11-20 Brahms Gmbh Biomarcador para la predicción de los primeros eventos adversos
US9561006B2 (en) * 2008-10-15 2017-02-07 The United States Of America As Represented By The Secretary Of The Navy Bayesian modeling of pre-transplant variables accurately predicts kidney graft survival
US8417541B1 (en) * 2009-08-27 2013-04-09 Cerner Innovation, Inc. Multi-stage model for predicting probabilities of mortality in adult critically ill patients
US20130066212A1 (en) * 2009-09-25 2013-03-14 Volcano Corporation Device and Method for Determining the Likelihood of a Patient Having a Clinical Event or a Clinically Silent Event Based on Ascertained Physiological Parameters
HUE027760T2 (en) 2010-04-09 2016-11-28 Critical Care Diagnostics Inc Soluble human ST-2 antibodies and assays
US10943676B2 (en) 2010-06-08 2021-03-09 Cerner Innovation, Inc. Healthcare information technology system for predicting or preventing readmissions
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
CN103796669B (zh) 2011-07-18 2016-11-09 重症监护诊断股份有限公司 治疗心血管疾病和预测运动疗法功效的方法
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
JP6302896B2 (ja) 2012-05-18 2018-03-28 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法
CN102830234A (zh) * 2012-08-10 2012-12-19 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
AU2013302451B2 (en) 2012-08-16 2019-01-17 Critical Care Diagnostics, Inc. Methods for predicting risk of developing hypertension
SG10201608854TA (en) * 2012-08-21 2016-12-29 Critical Care Diagnostics Inc Multimarker risk stratification
RU2510505C1 (ru) * 2012-11-15 2014-03-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ определения вероятности выраженной сердечной недостаточности в клинической картине инфаркта миокарда
GB201310290D0 (en) * 2013-06-10 2013-07-24 Univ Manchester Method for determining a probability of a major adverse cardiac event (MACE)
US20150199491A1 (en) * 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US20160256064A1 (en) * 2015-03-02 2016-09-08 Edward Harvey Estes, JR. Method and device to predict adverse cardiovascular events and mortality from an electrocardiogram-based validated risk score
EP3435846B1 (en) 2016-04-01 2024-08-07 Cardiac Pacemakers, Inc. Multi-disease patient management
AT518560B1 (de) * 2016-04-18 2018-01-15 Trumpf Maschinen Austria Gmbh & Co Kg Biegebalken für eine Schwenkbiegemaschine
EP3614908B1 (en) 2017-04-29 2024-10-09 Cardiac Pacemakers, Inc. Heart failure event rate assessment
US20200074313A1 (en) * 2018-08-29 2020-03-05 Koninklijke Philips N.V. Determining features to be included in a risk assessment instrument
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
WO2020236670A1 (en) 2019-05-17 2020-11-26 Regeneron Pharmaceuticals, Inc. Genome-based methods for reducing cardiovascular risk
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
JP2024508975A (ja) * 2021-03-08 2024-02-28 サノフイ 心血管疾患
EP4430635A1 (en) * 2021-11-11 2024-09-18 Beckman Coulter, Inc. Assessment of risk for major adverse cardiac event

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
US5217899A (en) 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP2732005B2 (ja) 1992-12-14 1998-03-25 眞一 富永 ヒトｓｔ２をコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
JPH0731479A (ja) 1993-02-23 1995-02-03 Shinichi Tominaga マウスｓｔ２ｌをコードするｄｎａ、該ｄｎａの発現産物、該ｄｎａを発現させることによる発現産物の製造方法
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
AU7235296A (en) 1996-08-23 1998-03-06 Human Genome Sciences, Inc. T1 receptor-like ligand ii
WO1998038311A1 (en) 1997-02-28 1998-09-03 Human Genome Sciences, Inc. T1/st2-receptor ligand iii
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
WO1998043630A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
EP0988552B1 (en) 1997-06-10 2010-11-24 Lpath, Inc. Methods for early detection of heart disease
ATE315228T1 (de) 1997-09-11 2006-02-15 Shionogi & Co Immunoassay zum bestimmen von bnp
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
GB9827348D0 (en) * 1998-12-12 1999-02-03 Univ Leicester Natriuretic peptide
EP1140137A2 (en) 1998-12-18 2001-10-10 Scios Inc. Method for detection and use of differentially expressed genes in disease states
WO2000073498A1 (en) 1999-06-02 2000-12-07 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
FR2795823B1 (fr) 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6677356B1 (en) 1999-08-24 2004-01-13 Medicure International Inc. Treatment of cardiovascular and related pathologies
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (en) 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
FR2807170B1 (fr) 2000-03-30 2002-06-28 Sipal Charniere elastique a frottement reduit
RU2002110275A (ru) 2000-08-22 2004-03-27 Дзе Брихэм Энд Уимен'З Хоспитал, Инк. (Us) Диагностика и лечение сердечно-сосудистых состояний
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6537221B2 (en) 2000-12-07 2003-03-25 Koninklijke Philips Electronics, N.V. Strain rate analysis in ultrasonic diagnostic images
FI20010019L (fi) 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
EP1666881B1 (en) 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
US6810284B1 (en) 2001-11-21 2004-10-26 Pacesetter, Inc. Implantable cardiac stimulation system and method for monitoring diastolic function
SI2336359T1 (sl) 2002-05-09 2016-08-31 The Brigham And Women's Hospital, Inc. 1L1RL-1 kot marker kardiovaskularne bolezni
WO2003100000A2 (en) 2002-05-24 2003-12-04 Tularik Inc. Amplification and overexpression of oncogenes
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US20040265926A1 (en) * 2002-11-21 2004-12-30 Leong Ng Bodily fluid markers of tissue hypoxia
AU2003299441A1 (en) 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
US20040133079A1 (en) 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20040220155A1 (en) 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20050250156A1 (en) 2003-10-31 2005-11-10 Shebuski Ronald J Detection of acute myocardial infarction biomarkers
CA3050151C (en) 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
US7781219B2 (en) 2003-12-05 2010-08-24 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2005291899A (ja) 2004-03-31 2005-10-20 Akira Matsumori 心疾患の検査法
EP1833766A1 (en) 2004-12-17 2007-09-19 Clearwater Systems Corp. Method and apparatus for treating fluids
WO2006077265A1 (en) 2005-01-24 2006-07-27 F. Hoffmann-La Roche Ag The use of bnp-type peptides and anp-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
US20070021977A1 (en) 2005-07-19 2007-01-25 Witt Biomedical Corporation Automated system for capturing and archiving information to verify medical necessity of performing medical procedure
JP4820192B2 (ja) 2006-03-17 2011-11-24 一般財団法人化学及血清療法研究所 急性冠症候群でのａｄａｍｔｓ１３の測定と利用
ES2646142T3 (es) * 2006-04-24 2017-12-12 Critical Care Diagnostics, Inc. Evaluación de la eficacia de un tratamiento en un sujeto en función de los niveles de ST2
US20090305265A1 (en) 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PL2482078T3 (pl) * 2006-05-01 2016-08-31 Critical Care Diagnostics Inc Diagnozowanie choroby sercowo-naczyniowej
PL2019965T3 (pl) 2006-05-02 2015-10-30 Critical Care Diagnostics Inc Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
EP2924440A3 (en) * 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
RU2312591C1 (ru) 2006-06-14 2007-12-20 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" Способ прогнозирования развития риска внезапной смерти у больных с лево- и правожелудочковой экстрасистолией
US20080233191A1 (en) 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
JP2010526555A (ja) 2007-05-11 2010-08-05 タフツ・メディカル・センター 加齢関連黄斑変性と関係するポリヌクレオチド及び患者のリスクを評価する方法
GB0713404D0 (en) 2007-07-11 2007-08-22 Integra Sp Ipr Ltd Altio graph
US20100267062A1 (en) 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
FR2923029B1 (fr) 2007-10-26 2009-11-20 Minima Lunettes de type sans entourage a branches filaires
HUE039963T2 (hu) 2008-04-18 2019-02-28 Critical Care Diagnostics Inc Súlyos káros szívesemények rizikójának elõrejelzése
WO2010025393A2 (en) * 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
CN102317790B (zh) 2008-11-11 2014-12-10 B.R.A.H.M.S有限公司 Adm在制备用于评估心力衰竭和/或呼吸短促的制剂中的应用
EP2499489B1 (en) 2009-11-13 2015-01-07 BG Medicine, Inc. Risk factors and prediction of myocardial infarction
US8258456B2 (en) 2009-11-27 2012-09-04 Himax Imaging, Inc. Image sensor
HUE027760T2 (en) 2010-04-09 2016-11-28 Critical Care Diagnostics Inc Soluble human ST-2 antibodies and assays
RU2618437C2 (ru) 2010-11-01 2017-05-03 Б.Р.А.Х.М.С Гмбх Оценка прогноза и риска пациентов с неспецифическими жалобами
RU2452394C1 (ru) 2010-11-09 2012-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования Ульяновский государственный университет Способ прогнозирования риска смерти больных хронической сердечной недостаточностью
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
US8615387B2 (en) * 2011-04-07 2013-12-24 Invensys Systems, Inc. Dynamic simulation of fluid filled vessels
CN103796669B (zh) 2011-07-18 2016-11-09 重症监护诊断股份有限公司 治疗心血管疾病和预测运动疗法功效的方法
JP6302896B2 (ja) 2012-05-18 2018-03-28 クリティカル ケア ダイアグノスティクス インコーポレイテッド 心室性頻脈性不整脈イベントを処置するためまたはそのリスクを予測するための方法
AU2013302451B2 (en) * 2012-08-16 2019-01-17 Critical Care Diagnostics, Inc. Methods for predicting risk of developing hypertension
SG10201608854TA (en) * 2012-08-21 2016-12-29 Critical Care Diagnostics Inc Multimarker risk stratification
US9665593B2 (en) * 2013-03-28 2017-05-30 International Business Machines Corporation Dynamically synching elements in file
JP6178687B2 (ja) 2013-09-27 2017-08-09 富士機械工業株式会社 グラビア塗工装置
US20150199491A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
US9934249B2 (en) 2014-06-03 2018-04-03 Conduent Business Machines Services, Llc Systems and methods for context-aware and personalized access to visualizations of road events
USD800332S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
ES2590213T3 (es) 2016-11-18
PL2269063T3 (pl) 2014-04-30
AU2016200697A1 (en) 2016-02-25
US11170896B2 (en) 2021-11-09
JP2014178322A (ja) 2014-09-25
EP2269063B1 (en) 2013-08-21
DK3093663T3 (en) 2018-09-24
EP2269063A2 (en) 2011-01-05
PL2827152T3 (pl) 2016-12-30
EP3378955A1 (en) 2018-09-26
AU2009236109A1 (en) 2009-10-22
HK1185658A1 (en) 2014-02-21
PT2827152T (pt) 2016-09-13
EP2660599B1 (en) 2014-09-10
EP3093663A1 (en) 2016-11-16
JP2011520098A (ja) 2011-07-14
AU2016200697B2 (en) 2018-01-04
DK2660599T3 (en) 2014-12-08
PT2660599E (pt) 2014-11-28
HRP20141056T1 (hr) 2015-01-02
JP5526122B2 (ja) 2014-06-18
JP2016048272A (ja) 2016-04-07
JP5873521B2 (ja) 2016-03-01
SI3093663T1 (sl) 2018-10-30
PL2660599T3 (pl) 2015-03-31
AU2018202350A1 (en) 2018-04-26
JP6788050B2 (ja) 2020-11-18
EP2827152A1 (en) 2015-01-21
US8090562B2 (en) 2012-01-03
ES2443125T3 (es) 2014-02-17
SI2269063T1 (sl) 2014-01-31
JP6484679B2 (ja) 2019-03-13
DK2269063T3 (da) 2013-12-02
EP2660599A1 (en) 2013-11-06
PL3093663T3 (pl) 2018-11-30
JP2019105645A (ja) 2019-06-27
US20180233229A1 (en) 2018-08-16
EP2827152B1 (en) 2016-06-08
US9965593B2 (en) 2018-05-08
SI2827152T1 (sl) 2016-10-28
PT2269063E (pt) 2013-11-27
JP6200975B2 (ja) 2017-09-20
HK1206419A1 (en) 2016-01-08
JP2021039108A (ja) 2021-03-11
DK2827152T3 (en) 2016-09-12
AU2009236109B2 (en) 2015-11-05
US20090264779A1 (en) 2009-10-22
ES2687401T3 (es) 2018-10-25
US20130244236A1 (en) 2013-09-19
HUE029880T2 (en) 2017-04-28
CA2720674A1 (en) 2009-10-22
EP3093663B1 (en) 2018-06-13
HUE039963T2 (hu) 2019-02-28
US20120065897A1 (en) 2012-03-15
WO2009129454A2 (en) 2009-10-22
SI2660599T1 (sl) 2014-12-31
HRP20131100T1 (hr) 2014-01-31
EP2269063A4 (en) 2011-05-04
JP2017203784A (ja) 2017-11-16
ES2525029T3 (es) 2014-12-16
US20150081224A1 (en) 2015-03-19
HK1152750A1 (en) 2012-03-09
WO2009129454A3 (en) 2010-01-28
US9886553B2 (en) 2018-02-06

Similar Documents

Publication Publication Date Title
SI2827152T1 (sl) Napovedovanje tveganja večjih neželenih srčno-žilnih dogodkov
GB2473392B (en) Methods of diagnosis
IL209855A0 (en) Supression of neuroedocrine diseases
GB0807612D0 (en) New use of surfactant
EP2438246A4 (en) CONSTRUCTION ASPECTS
AP2008004406A0 (en) Methods of managing timberland
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
GB0915464D0 (en) Improved method of determining metabolic function
EP2332112A4 (en) PORTFOLIO PART REFERENCE
AP2784A (en) Methods of managing timberland
ZA201006228B (en) Combined use of cholestanol derivative
EP2247746A4 (en) METHOD FOR MONITORING METABOLIC WAYS
GB0814238D0 (en) Enhancement of electrochemical response
EP2126564A4 (en) DIAGNOSTIC PROCEDURE
GB0821185D0 (en) Walking aid
PL117894U1 (pl) Uchwyt montażowy elementów konstrukcyjnych
TWM347258U (en) Structure of chisel
GB0811723D0 (en) Wrist rest
GB2452842B (en) Method of increasing activity
HU0800656D0 (en) Effective use of tea-composition
GB0816865D0 (en) Enabling monitoring of components
TWM389452U (en) Modeling and fixing structure of shoe
IL212859A0 (en) Diagnosis of multiple sclerosis
GB0906222D0 (en) Methods for screening of therapeutic agents
PL384349A1 (pl) Zasuwa o uproszczonej budowie